NCT04838743已完成不适用
A Non-interventional, Single-arm, Multicentre, Prospective Study Investigating the Glycaemic Control and Treatment Pattern Associated With the Use of Xultophy® (IDegLira) in a Real-world Adult Population With Type 2 Diabetes Mellitus in Japan. GOAL (Glycaemic Outcome Assessment IDegLira) Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 244
- 试验地点
- 42
- 主要终点
- Change in local laboratory measured HbA1c (Glycated haemoglobin )
研究概览
简要总结
The purpose of this study is to collect information on how Xultophy® works with other oral anti diabetic medication in patients with type 2 diabetes.
Participants will get Xultophy® as prescribed by the study doctor. The study will last for about 26 weeks. Participants will be asked questions about health and diabetes treatment and lab tests as part of normal doctor's appointment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- •The decision to initiate treatment with commercially available Xultophy® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
- •Male or female, age above or equal to 20 years at the time of signing informed consent
- •Diagnosed with T2DM (Type 2 diabetes mellitus ) above or equal to 180 days prior to initiation of Xultophy® treatment.
- •Treated with any oral anti-hyperglycaemic medication(s), except for oral GLP-1 RAs, for at least 60 days prior to initiation of Xultophy® treatment.
- •Available and documented HbA1c value less or equal to 12 weeks prior to initiation of Xultophy® treatment.
排除标准
- •Previous participation in this study. Participation is defined as having given informed consent in this study.
- •Participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days before prior to initiation of Xultophy® (Simultaneous participation in a trial with the primary objective of evaluating an approved or non-approved investigational medicinal product for prevention or treatment of COVID-19 disease or postinfectious conditions is allowed if the last dose of the investigational medicinal product has been received more than 30 days before screening.).
- •Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 60 days prior to initiation of Xultophy® treatment. However, short term insulin treatment for a maximum of 14 days prior to initiation of Xultophy® treatment is allowed, as is prior insulin treatment for gestational diabetes.
- •Previous treatment with Xultophy®.
- •Female who is known pregnant, breast-feeding or intends to become pregnant.
- •Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
- •Known or suspected hypersensitivity to the active substance or to any of the excipients as specified in the approved Xultophy® label in Japan.
研究组 & 干预措施
IDegLira
Real-world adult population with type 2 diabetes mellitus in Japan.
干预措施: IDegLira (Drug)
结局指标
主要结局
Change in local laboratory measured HbA1c (Glycated haemoglobin )
时间窗: From baseline (Visit 1) to 26 weeks (Visit 3)
% point
次要结局
- Change in local laboratory measured FPG (Fasting plasma glucose )(From baseline (Visit 1) to 26 weeks (Visit 3))
- Number of patient-reported non-severe hypoglycaemic after initiation of treatment with Xultophy®(From baseline (Visit 1) to 26 weeks (Visit 3))
- Number of patient-reported severe hypoglycaemic after initiation of treatment with Xultophy®(From baseline (Visit 1) to 26 weeks (Visit 3))
- Change in concomitant OAD(s) (Oral antidiabetic drugs ) including change in number, class, and frequency of concomitant OAD(s), after initiation of treatment of Xultophy® (Yes/No)(From baseline (Visit 1) to 26 weeks (Visit 3))
- Change in daily dose of Xultophy®(From baseline (Visit 1) to 26 weeks (Visit 3))
研究者
研究点 (42)
Loading locations...
相似试验
已完成
不适用
A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in ItalyDiabetes Mellitus, Type 2NCT04666987Novo Nordisk A/S359
已完成
不适用
Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaDiabetes Mellitus, Type 2NCT04952779Novo Nordisk A/S750
终止
4 期
Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)Pulmonary Arterial HypertensionNCT02968901Actelion46
进行中（未招募）
3 期
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic AsthmaEosinophilic AsthmaAsthma AttackEosinophilic AsthmaNCT05748600Areteia Therapeutics600
撤回
3 期
An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient InsomniaTransient InsomniaNCT03338764Sequential Medicine Ltd